Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
NCT01962896Phase 2Terminated
- Start
- Jan 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sirolimus and erlotinib in germ cell tumor (GCT). Primary endpoint: Progression-Free Rate at 16 weeks. Started Jan 2014; status: terminated.
02
Drugs
sirolimuserlotinib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT01962896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962896.